Exactech Receives Patent For Rotating Bearing Knee, Optetrak RBK System

February 26, 2009 at 2:00 pm Leave a comment


Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that is has been issued U.S. Patent 7,422,605,B2 for its rotating bearing knee prosthesis, Optetrak® RBK™.




Exactech’s Optetrak RBK knee has been an important part of the company’s total knee business outside the U.S., particularly in Europe, where rotating bearing knee designs are popular. Since 2006, Exactech has sponsored a U.S. Investigational Device Exemption (IDE) clinical trial for Optetrak RBK, which will support its future submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration.



About Exactech




Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and Australia, in addition to more than 30 markets in Europe, Asia and Latin America. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com http://www.hawkassociates.com.




An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm.




Investors may contact Chief Financial Officer Jody Phillips at 352-377-1140 or Julie Marshall or Frank Hawkins, Hawk Associates Inc., at 305-451-1888, e-mail: exactech@hawkassociates.com. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.




This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.



Exactech

[Via http://www.medicalnewstoday.com]

Advertisements

Entry filed under: Uncategorized.

Travel Fellowships To Experimental Biology 2009 In New Orleans Received By 40 Minority Scientists Obama’s Health Plan

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Archives

Top Clicks

  • None

Blog Stats

  • 15,534 hits

%d bloggers like this: